127 related articles for article (PubMed ID: 15778424)
21. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
22. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.
Hulot JS; Montalescot G; Lechat P; Collet JP; Ankri A; Urien S
Clin Pharmacol Ther; 2005 Jun; 77(6):542-52. PubMed ID: 15961985
[TBL] [Abstract][Full Text] [Related]
23. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
24. Comparison of renal function markers in Kuwaiti patients with sickle cell disease.
Marouf R; Mojiminiyi O; Abdella N; Kortom M; Al Wazzan H
J Clin Pathol; 2006 Apr; 59(4):345-51. PubMed ID: 16567469
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases.
Michel M; Habibi A; Godeau B; Bachir D; Lahary A; Galacteros F; Fifi-Mah A; Arfi S
Semin Arthritis Rheum; 2008 Dec; 38(3):228-40. PubMed ID: 18177923
[TBL] [Abstract][Full Text] [Related]
26. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment.
Swan SK; Smith WB; Marbury TC; Schumacher M; Dougherty C; Mico BA; Villano SA
J Clin Pharmacol; 2007 Feb; 47(2):209-17. PubMed ID: 17244772
[TBL] [Abstract][Full Text] [Related]
28. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
Friedrisch JR; Prá D; Maluf SW; Bittar CM; Mergener M; Pollo T; Kayser M; da Silva MA; Henriques JA; da Rocha Silla LM
Mutat Res; 2008 Jan; 649(1-2):213-20. PubMed ID: 17988936
[TBL] [Abstract][Full Text] [Related]
29. Effect of renal function on the pharmacokinetics of palifermin.
Gillespie B; Zia-Amirhosseini P; Salfi M; Kakkar T; Wang J; Gupta S; Smith B; Robson R; Sullivan JT
J Clin Pharmacol; 2006 Dec; 46(12):1460-8. PubMed ID: 17101745
[TBL] [Abstract][Full Text] [Related]
30. Influence of renal function and diet on acid-base status in chronic kidney disease patients.
Leal VO; Delgado AG; Leite M; Mitch WE; Mafra D
J Ren Nutr; 2009 Mar; 19(2):178-82. PubMed ID: 19218046
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
Wiczling P; Liem RI; Panepinto JA; Garg U; Abdel-Rahman SM; Kearns GL; Neville KA
J Clin Pharmacol; 2014 Sep; 54(9):1016-22. PubMed ID: 24729271
[TBL] [Abstract][Full Text] [Related]
32. Age-related differences in renal function at onset of renal replacement therapy in chronic kidney disease stage 5 patients.
Balogun SA; Balogun RA; Evans J
QJM; 2006 Sep; 99(9):595-9. PubMed ID: 16905750
[TBL] [Abstract][Full Text] [Related]
33. Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease.
Conran N; Saad ST; Costa FF; Ikuta T
Ann Hematol; 2007 Apr; 86(4):255-61. PubMed ID: 17205286
[TBL] [Abstract][Full Text] [Related]
34. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
Estepp JH; Wiczling P; Moen J; Kang G; Mack JM; Liem R; Panepinto JA; Garg U; Kearns G; Neville KA
Br J Clin Pharmacol; 2018 Jul; 84(7):1478-1485. PubMed ID: 28884840
[TBL] [Abstract][Full Text] [Related]
35. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
Mellouli F; Bejaoui M
Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
[TBL] [Abstract][Full Text] [Related]
36. Effect of hydroxyurea on the deformability of the red blood cell membrane in patients with sickle cell anemia.
Athanassiou G; Moutzouri A; Kourakli A; Zoumbos N
Clin Hemorheol Microcirc; 2006; 35(1-2):291-5. PubMed ID: 16899945
[TBL] [Abstract][Full Text] [Related]
37. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease.
Hassan Y; Al-Ramahi RJ; Aziz NA; Ghazali R
Ann Pharmacother; 2009 Oct; 43(10):1598-605. PubMed ID: 19776297
[TBL] [Abstract][Full Text] [Related]
38. Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.
Odièvre MH; Bony V; Benkerrou M; Lapouméroulie C; Alberti C; Ducrocq R; Jacqz-Aigrain E; Elion J; Cartron JP
Haematologica; 2008 Apr; 93(4):502-10. PubMed ID: 18322255
[TBL] [Abstract][Full Text] [Related]
39. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
